---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-019576"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2026-06-04T21:20:09+00:00"
generated_at: "2026-06-04T21:22:52.904416+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals closes $22.3M public offering of common stock at $3.50/share

## Summary
- Priced 5,714,286 shares at $3.50; underwriters' option for 857,142 shares exercised, gross proceeds $22.3M.
- Net proceeds estimated ~$21.6M after underwriting discounts and expenses; funds working capital and growth.
- BTIG acted as lead bookrunner; Lucid Capital Markets as joint bookrunner.
- Offering led by B Group Capital, with participation from Columbia Threadneedle, Corbets Capital, Venture 76, and Mossrock Capital.
- Shares issued under effective S-3 shelf (No. 333-288205); closed June 4, 2026.

## SEC filing metadata
- accession: 0001437749-26-019576
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2026-06-04T21:20:09+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/0001437749-26-019576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/nrxp20260603_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-019576
- JSON: https://secwatch.observer/filing/0001437749-26-019576.json
- Plain text: https://secwatch.observer/filing/0001437749-26-019576.txt

## Key facts
- Material Agreements
  NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with BTIG, LLC valued at approximately $18.8 million (or $21.6 million, if the Underwriters’ option to purchase additional sh (effective 2026-06-03).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: BTIG, LLC
  - Value: approximately $18.8 million (or $21.6 million, if the Underwriters’ option to purchase additional sh
  - Effective: 2026-06-03
  source text: On June 3, 2026, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BTIG, LLC, as representative of the several underwriters listed in Schedule A thereto (the “ Underwriters ”) in connection with a public offering of an aggregate of 5,714,286 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), by the Company at a price to the public of $3.50 per share (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/0001437749-26-019576-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.